
price data provid thomson reuter
number may add due round
initi under-perform eye
initi coverag under-perform rate price target
share outpac sector year vs nbi ahead
phase data paroxysm nocturn hemoglobinuria pnh howev
see meaning challeng assum phase pegasu studi
meet primari endpoint switch guarante ultomiri
alreadi convert us pnh market unclear may impact
util geograph atrophi dri age-rel macular degener
ga provid anoth opportun question dose-depend
relationship new onset exud see clinic risk even
assum success pnh ga materi revenu unlik
materi thu see potenti financi risk current cash
runway per recent file expens reduct could extend window
potenti launch see challeng dynam
fli high pegasu pnh incid infrequ potenti switch
soliri import naiv patient pivot pnh
switch data anticip januari high probabl achiev primari
endpoint translat commerci success think need
show hb stabil includ broader benefit across clinic
endpoint transfus avoid and/or breakthrough hemolysi
drive adopt price could anoth switch lever patient pool
like encompass patient challeng see mani would
migrat particularli ultomiri convers continu despit concern
model pnh revenu begin
eye futur ga opportun reduc ga lesion growth rate
phase filli studi monthli every-other-month
eom dose howev new onset exud manifest
monthli eom patient vs sham current estim assum
success derbi oak pivot studi complet market approv
although assum phase data mirror phase result see limit
commerci potenti given absenc vision gain assum mid-
singl digit share usag translat ga revenu
respect
risk/reward seem challeng could wrong
commerci estim consensu simpli may conserv
howev note hold cash runway
would like fall regulatori approv expens reduct
could extend runway even commerci assumpt
materi revenu pnh ga unlik manifest thu
see risk/reward skew downsid share trade
wedbush secur seek busi compani cover
research report thu investor awar firm may
conflict interest could affect object report investor
consid report singl factor make invest decis
pleas see page report analyst certif import
inc clinical-stag biotechnolog compani focus develop novel therapi
target complement system advanc asset deriv compstatin
evalu pivot studi paroxysm nocturn hemoglobinuria pnh geograph atrophi dri age-
relat macular degener ga beyond indic also evalu potenti
complement-driven diseas hold cautiou bia share anticip phase pegasu studi
pnh like meet endpoint competit landscap challeng one soliri ultomiri
signific traction ultra-rar pnh market ga reduc lesion size phase studi
occur dose-depend incid new onset exud although estim like conserv
setup appear challeng cash runway earliest potenti approv like
approv pnh switch
market
complet studi
studi
broad label
improv vision lesion
growth wet
pnh market may small
patient challeng identifi
fail demonstr
benefit ga studi safeti
jan potenti top-lin data pegasu pivot
studi pnh switch
complet enrol pivot ga studi derbi
price target deriv sum-of-part dcf
model examin potenti cash flow deriv
discount back per year
headquart
clinical-stag biotechnolog compani focus
develop novel therapi target
crestwood ky
remain advanc product
candid repres key valu driver
current estim
follow recent ra achillion
pharmaceut acquisit believ
posit investor sentiment complement-focus
compani
creat bluematrix
tabl content
diseas background complement system clinic applic
complement immun respons complement system overview
paroxysm nocturn hemoglobinuria pnh overview epidemiolog standard
geograph atrophi ga overview epidemiolog standard
pnh program clinic effort paddock pharoah
pegasu focu right pivot switch studi
ga program current state develop
valuat deep dive top bottom
minut macro current state biotech sector valuat
tabl figur
figur overview valuat sum-of-part dcf analysi
figur overview complement pathway relev
figur hemolysi mechan influenc complement
figur comparison complement-target therapi
figur schemat macular region
figur comparison dri vs wet
figur overview phase paddock design
figur overview phase ga studi design derbi oak
figur phase filli studi baselin trait new onset exud month
summari conclus initi coverag apelli pharmaceut inc
under-perform rate target look stori see multipl pivot
program underway lead asset near-term readout januari howev even
assum clinic success indic paroxysm nocturn hemoglobinuria
pnh geograph atrophi ga see challeng setup ahead pnh assum
pegasu meet endpoint question stand us term real address
market size clinic meaning improv regulatori path forward
ga phase filli studi demonstr reduct ga lesion growth rate versu
sham improv function declin vision continu well dose-
depend incid new-onset exud pair issu cash runway
per recent file see challeng setup share could wrong
follow recent rarx achn acquisit take certainli real possibl
addit data could better anticip element thesi follow
thing go bump pnh
pnh repres orphan hematolog disord character fatigu bleed
flu-lik symptom introduct alxn soliri chang pnh standard care
recent introduct alxn ultomiri offer addit improv
notabl extend dose interv move everi week soliri everi
week ultomiri note despit gain remain subset pnh patient
anem transfus depend evalu two pivot pnh studi
potenti altern soliri monotherapi option treatment-nav pnh
hit best shot pnh
under-perform rate predic sever factor first foremost even pegasu
success complet read elimin clinic risk see commerci risk suggest
soliris-tr pnh patient remain anem g/dl may candid
studi suggest true number need altern regimen may closer
toward soliris-tr patient either way pnh compris ultra-rar condit
estim address switch-pati pool could patient step back
also see question path market term label may look within
switch popul also drug gain access treatment-nav pnh
popul final even assum approv amidst ultomiri market
convers potenti once-weekli subcutan devic launch see challeng
setup on-bodi injector requir per week dose necessit profil
clearli ga
addit effort underway geograph atrophi ga age-rel macular
degener also on-going manag guid complet enrol
pivot studi couldnt repres anoth opportun agre ga repres
signific caus blind current approv therapi larg
address market potenti million patient global assign credit
ga opportun compris two-third overal valuat nevertheless
histori suggest potenti mechanistic/clin risk ga challeng diseas target base
prior clinic failur complement space examin prior data less
concern compani chang primari endpoint methodolog remain cautiou
opportun incid new-onset exud occur dose-depend
manner import confound could impact commerci uptak
king
past year mark import period compani complet deal
sfj secur fund complet pnh pivot studi well convert note
offer provid fund ga develop program time critic prior
deal held go concern risk languag less month cash fund
oper compani hold cash report current quarterli
cash burn rate exce rise latest file indic current cash
provid runway fourth quarter reduct spend could like extend
runway howev ga pivot readout project would pnh regulatori decis
assum submiss creat addit complex even effort remain
track bottom line much go right support current valuat even
see challeng upsid scenario describ herein given share current trade
see risk/reward skew downsid
figur illustr current develop pipelin septemb
note current pipelin effort focu primarili upon molecul deriv
compstatin two primari formul subcutan formul system
condit intravitr formul use ophthalm indic see
advanc effort within pnh ga indic program
current phase program soon also begin advanc anoth molecul
howev purpos report concentr analys
tabl summar relev catalysts/data mileston relev aplss
develop strategi deem like potenti impact share
impact near term pegasu phase data pnh patient
altern soliri treatment although describ detail herein recal
studi compar week chang baselin hemoglobin level treated-
patient versu soliri monotherapi treatment project januari readout
describ detail herein deriv price target share primarili
use sum-of-part dcf analysi valuat methodolog examin cash
flow gener per-ind basi current assign credit
earlier indic autoimmun hemolyt anemia complement primari
analysi also use compar multipl valuat approach price-to-earnings p/ put initi
result context howev import note believ sum-of-part dcf strategi
repres rigor approach development-stag biotech absent histori
earn commerci experi
figur illustr overal valuat contribut specif program well
aplss current net cash pro forma basi follow compani recent
convert note offer pleas see pp comprehens descript
figur overview valuat sum-of-part dcf analysi
diseas background complement system clinic
complement immun respons complement system overview
complement system refer subgroup immun system compris seri
proteins/enzym function togeth signal cascad system first identifi
respons mechan bacteri pathogen figur illustr three
main pathway complement system classic altern lectin pathway
regardless trigger event three pathway converg similar point known
complement protein convertas signal process progress via lytic pathway
end cascad reach membran attack complex form
complement cascad becom activ aberrantli case variou
autoimmun disord begin target non-pathogen cell red blood cell instead
pathogen cell result lead differ diseas state figur illustr
variou pathway compon complement system also
development-stag approv agent target differ player
figur overview complement pathway relev
paroxysm nocturn hemoglobinuria pnh overview epidemiolog standard
pnh repres ultra-rar genet condit red blood cell come attack
immun system underli genet driver diseas via acquir mutat
piga gene clinic perspect pnh repres chronic disord variou
symptom within hemolyt anemia disord like two main type
hemolysi red blood cell lysi occur intravascular extravascular hemolysi
former condit hemolysi occur within blood vessel larg complement-
mediat process via extravascular hemolysi character phagocytosi within organ
compart liver spleen process also mediat via
latter process hypothes may offer addit control hemolysi
outsid soliri treatment
figur hemolysi mechan influenc complement
classic form diseas pnh usual manifest dark urin cola color
night result intravascular hemolysi color clear cours day
due destruct red blood cell mani clinic
manifest diseas like unsurpris fatigu dyspnea hemoglobinuria
abdomin pain chest pain accord studi pnh patient conduct
intern pnh registri approxim respond work work less due
pnh symptom
pnh suspect patient present sign hemoglobinuria
increas lactat dehydrogenas ldh level abdomin cerebr vein thrombosi
sign hemolysi diagnos pnh flow cytometri analysi erythrocyt granulocyt
perform identifi antibodi direct gpi-ap confirm diagnosi
also accomplish via character potenti piga mutat patient categor
one three form diseas
pnh aplast anemia anoth bone marrow disord
mutat drive pnh occur low frequenc person per thu
consid ultra-rar condit pnh registri held data
approxim pnh patient typic age diseas onset due
rare natur diseas diagnosi may take mani year obtain patient
encount differ specialist treat physician
approv introduct soliri pnh market brought meaning chang
current standard care work report loschi colleagu
retrospect analys compar pnh patient treat prior introduct soliri
patient treat soliri found improv overal surviv soliri
histor well fewer thrombot event soliri histor similar find
report via retrospect analys conduct pnh registri
ultomiri recent approv launch sever market like
necessit revisit among commun regard guidelin focu prior
treatment guidelin emphas soliri treatment figur summar
current treatment algorithm major patient high-diseas activ
funnel toward soliri regimen tandem support treatment folic acid iron
replac transfus
note case bone marrow defici non-hemolyt pnh treatment underli diseas
prioriti high diseas activ support treatment includ folic acid iron replac
approv introduct alxn ultomiri chang current treatment landscap
pnh within us launch product septemb manag
disclos convert roughli exist soliri patient toward ultomiri
tabl compar two product soliri ultomiri
across varieti product measur three agent target complement system apl-
target upstream protein known complement soliri ultomiri
figur comparison complement-target therapi
geograph atrophi ga overview epidemiolog standard
age-rel macular degener known one lead caus blind
character retin deterior time macular region central
retin region primarili affect figur shown depict variou compon
eye includ retina macular region macula character dens
popul photoreceptor cell enabl retina focu visual object
figur schemat macular region
macular region begin deterior patient initi problem vision
rang blurri wavi vision diseas progress patient increas visual
disrupt becom blind within two form diseas dri
wet case begin dri time convert wet
tabl contrast two subtyp note dri wide observ
figur comparison dri vs wet
beyond categori import note three distinct stage
diseas earli patient experi vision loss stage potenti deposit
within retina may observ eye exam intermedi patient begin
experi vision loss may central vision loss depict prior figur
eye exam begin character retin deposit morpholog chang late-stag
patient experi central vision loss within late-stag popul
patient develop geograph atrophi ga ga region within retina
die atrophi atrophi gener blind spot visual field shown
prior figur diagnosi ga perform ophthalmolog exam incorpor
retin imag retin color photograph optic coher tomographi oct per
preval increas age demonstr sever publish meta-
genentech estim approxim patient us
data estim us adult late-stag somewhat
consist nation institut project late-stag
patient us
ga treatment complement strategi
ga repres complex multi-factori disord thought tie complement
dysfunct inflamm oxid studi demonstr potenti genet
link variant locat near differ complement gene cfi
present approv therapi address ga although mani
develop rel agent develop repres one
advanc candid particularli failur roch lampalizumab phase studi
prior effort explor potenti complement target therapeut potenti beyond
lampalizumab also evalu soliri potenti ga treatment complet phase
studi examin intraven soliri two differ dose versu placebo studi
power detect improv versu placebo improv observ note
soliri subject convert wet although placebo subject convert
cours studi one hypothesi studi failur deliveri
agent like inadequ iv versu intravitr administr howev anoth potenti
explan could complement activ may signific driver ga patholog
ga repres multi-factori although cascad like play role
pathogenesi failur clinic studi complement inhibitor led expert
question role versu pathogenesi mechan and/or minimum explor potenti
biomark help identifi may realiz benefit complement inhibit
licens complement protein inhibitor program
univers pennsylvania origin peptid emerg studi
name compstatin
activ primat
subsequ studi focus optim drug-lik properti compstatin eventu
yield peptid deriv known see figur
stabil issu limit half-lif gener via pegyl
sever technolog explor ultim select pegyl strategi
link fragment result molecul exhibit improv
chemic stabil pharmacokinet half-lif versu move hour multipl
pnh program clinic effort paddock pharoah
complet two clinic studi pnh known paddock pharoah
figur shown illustr paddock open-label trial design evalu
monotherapi treatment-nav pnh patient studi focus subject
receiv transfus past year baselin ldh level upper-limit-of-norm uln
note paddock daili subcutan inject use deliv
dose subsequ studi incorpor on-bodi injector devic deliv
higher dose differ interv per week
figur overview phase paddock design
report interim data patient complet week treatment
dose see figur across week subject realiz mean
improv hb level exclud one subject underli comorbid
pegasu focu right pivot switch studi
initi pivot phase program known pegasu figur illustr
overal design studi studi recruit subject current stabl
soliri eculizumab dose enrol subject go one-month run-in period
patient receiv combin soliri follow run-in period subject
random receiv monotherapi soliri week primari endpoint
focu chang hemoglobin week time point
ga program current state develop
recent publish detail data phase filli studi studi
met primari endpoint mean chang baselin month squar root
ga area monthli every-other-month eom inject yield
reduct growth rate respect see
lesion growth trend appear favor note effect function outcom
best correct visual acuiti bcva subject continu experi declin
vision regardless treatment arm
advanc two phase studi known derbi oak figur shown
illustr design attribut two ident studi perhap notabl
studi incorpor dose administ either monthli everi month
sham subject receiv inject frequenc dose pattern
incorpor phase filli studi
figur overview phase ga studi design derbi oak
one import point highlight ga lesion area calcul differ
manner phase studi compar methodolog use phase primari
endpoint phase filli studi evalu baselin month mean chang
squar root ga lesion size howev phase studi primari endpoint
examin chang total area ga lesion size convers manag
learn appli chang total area ga lesion size assess would
chang outcom phase studi thu provid confid unlik
signific impact phase studi derbi oak studi power
detect degre treatment effect observ phase studi
noteworthi highlight prior lampalizumab data roch given role factor
inhibitor figur illustr chang ga area phase mahalo studi
compar two dose lampalizumab versu primari endpoint mahalo
studi focus mean chang lesion area baselin month chang
highlight chang month focu derbi oak focus
subgroup genet carrier cfi greater reduct lesion area growth
reduct lampalizumab treatment versu sham control see
lampalizumab advanc duplic phase pivot studi explor lampalizumab
dose administ everi everi week versu sham primari endpoint
focus mean chang baselin ga lesion area week studi also
stratifi patient cfi biomark statu ultim neither phase studi show
meaning reduct ga lesion size compar sham group see figur
note consist respons sham group demonstr increas ga lesion
area cours week treatment period
although phase studi demonstr faster rate declin among cfi-posit subject
effect replic phase studi overal popul cfi-posit
subject exist roughli chang baselin lesion area see panel
figur
learn appli lampalizumab studi one hand
target factor repres distinct point complement cascad compar factor
fall within lectin pathway leav complement pathway avail activ
cascad blockad repres downstream point pathway also
central hub spot may abl prevent activ via rout thu first
take-away lampalizumab may simpli take aim appropri
target one compensatori mechan continu drive progress
key question address whether target repres better approach versu factor
discuss detail one potenti issu relat new onset case
exud filli studi case new onset exud appear occur dose-
depend manner month treatment month monthli every-
spoke manag indic none exud find
consid classic cnv addit may treat aggress clinic trial
set consid addit possibl explan dose-depend effect note
one report suggest prevent cleavag accumul
could occur contribut develop derbi
oak studi provid import assess determin uniqu phase
effect note manifest appear distinct earlier lampalizumab studi
phase phase report differ versu sham group case new-onset
figur take closer look consensu revenu expect surround variou dri
amd/ga development program via evaluatepharma shown
consensu estim period project nearli market
estim compris take investor expect appear high
compani success ga indic
note numer figur chart repres total revenu estim agent period
addit readout better inform potenti success respect
program given current inform concern ga pnh program
addit unclear us whether pnh data clinic meaning follow
section step concern detail
issu increas convers wet among ga patient
 event data present uk studi provid
overview unmet need ga patient studi popul consist
patient diagnosi form across ten retin center uk
within group ga cohort encompass patient overal popul
among patient bilater ga affect eye progress choroid
neovascular cnv patient lost letter line visual acuiti see
figur red dash circl
howev filli phase studi report appear dose-depend
increas convers wet figur summar baselin subject demograph
result new onset exud month treatment either monthli
monthli everi month eom intravitr inject sham inject
note differ treatment arm rel balanc regard prior histori
cnv fellow eye
despit balanc demograph studi initi note separ case new
onset exud month time point sham-pool subject develop
new onset exud studi eye subject experienc dose-depend new
onset exud respect monthli eom group see figur
major new onset case associ treatment appear occur
subject prior histori cnv fellow eye
figur phase filli studi baselin trait new onset exud month
note eom everi month
phenomena appear limit note case report
lampalizumab studi soliri placebo patient higher rate develop wet
cours studi soliris-tr patient
phase filli studi demonstr reduct lesion growth monthli
dose versu sham group eom group experienc reduct month versu
sham subject although lampalizumab pivot design power
detect reduct ga lesion rel sham control dropout rate assum
differ ga lesion area across treatment arm week
consid wet space one advantag intravitr anti-angiogen
therapi regeneron eylea note drug abl larg curtail vision loss even
improv vision wet patient consid rout administr
wonder motiv ga patient continu monthli eom dose frequenc
without improv function endpoint
step back note genet variant studi suggest role complement
involv ga remain seen actual role later stage
point patient present ga later stage diseas
mani facet diseas still well character exampl includ
stage diseas intervent still possibl categor identifi subtyp
diseas amen complement treatment
issu competit crowd pnh marketplac
convers kol acknowledg certain patient realiz
full benefit soliri publish literatur offer support even alxn recent
commentari follow achn acquisit indic compris exist soliris-
treat pnh market addit see prior exampl orphan
diseas space patient readili switch new brand agent one exampl seen
fabri diseas area genzym face suppli issu fabrazym shire replag
abl take market share howev scenario switch driven need price
one lever may compet draw potenti candid limit
incid new pnh case switch market relev
step back think pnh landscap may evolv earli
ultomiri convers like nearli complet weekli subcutan option set
launch anoth dynam consid separ see earliest potenti
soliri biosimilar entri period program continu
player show modest hb chang improv transfus unclear
us well fit competit landscap
issu relev address market pnh
even demonstr improv hb also show improv transfus
rate question surround true address market
manag talk need addit treatment option pnh patient
remain unmet need nearli soliris-tr patient still requir least one
agre like soliri pnh patient incomplet
control studi would suggest popul larg
exampl mckinley et al data set indic patient need deriv
singl center experi spoke indic soliris-tr
pnh patient estim transfus depend therapi check-in
kol also suggest like small percentag alreadi small overal market final
shown figur respons soliri may also influenc underli
within group patient consid partial minor respond
remain transfus depend part due aplast anemia bone marrow failur
case envis abl provid meaning benefit thu
mediat extravascular hemolysi evid subject see
opson known phenomenon occur soliris-tr pnh patient literatur
report though appear somewhat conflict term clinic also note
vari definit literatur surround constitut clinic extravascular hemolysi
take high-level view even appropri address market soliris-
treat patient still compris small market opportun like make patient
follow section describ current market model market
opportun pnh ga set detail
figur illustr market model pnh set overal estim
pnh patient global us compris roughli pnh patient
among us pnh popul assum approxim patient current
receiv treatment alxn soliri ultomiri key assumpt drive current
market estim would avail altern treatment either
aforement complement inhibitor presum addit data would necessari
agent use treatment-nav pnh patient
shown figur assum earliest potenti us commerci launch
would stage assum treatment-nav label would requir addit
data earliest potenti commerci entri approxim one year approv
treatment-experienc indic switch market
among soliris-tr patient assum like candid switch treatment would
patient remain transfusion-depend follow treatment soliri and/or ultomiri
septemb report convert approxim half us pnh market
soliri ultomiri estim vari larg market may
assum encompass roughli soliri market assign credit
us eu pnh switch market present see us switch market model use
prior clinic trial data soliri estim approxim
exist soliris/ultomiri popul still requir period transfus larger
conting may still hemoglobin level normal assum like
popul seek altern therapi patient requir signific clinic
intervent discuss greater detail risk/reward analysi section
import note estim assum label would restrict usag sole
soliri patient word assum util would permit use
either soliri ultomiri import note conduct studi
compar drug ultomiri
put simpli price difficult project assum success path forward ga
realiz soliris-typ price would limit patient access given ga encompass million
patient assum differenti price across two indic independ
amount drug provid theori administ pnh patient via on-
bodi deliveri devic larg quantiti ga indic would requir smaller amount
deliv via intravitr inject
current estim assum annual price point per patient per year
us pnh market would theoret repres discount soliri
ultomiri price pnh indic consist orphan diseas therapi also
assum price pariti across geographi mean price also incorpor
eu price point figur illustr price assumpt appli standard
discount variou payer categori deriv net annual price per patient
figur illustr current market model ga indic
manag guid complet enrol pivot derbi oak studi
end primari endpoint focus chang ga lesion size month
studi follow subject month thu assum pivot phase derbi
oak program yield success top-lin data would set stage
base current program assum patient us present late-stag
ga focus patient wors vision cohort assum
util would priorit toward patient without presenc wet histori
cnv given unexplain dose-depend increas new onset exud
prior studi reduc address market us patient see figur
within eu market use framework assum total address
market patient
previous state assum price util separ price band across
pnh ga indic use price ga premium current annual
price brand wet therapi start point per patient although
acknowledg wet market repres smaller patient popul compar ga
opportun also unclear whether dose option monthli vs eom would reach
market physician would opt less frequent inject address dynam use
complianc rate see
valuat deep dive top bottom
minut macro current state biotech sector valuat
tabl summar current valuat metric large-cap mid-cap commerci
stage biotechnolog compani see relev peer group mid-cap
group highlight mid-cap commerci peer group current trade mean
note price
compar histor basi figur attempt put tempor context
around current sector-level valuat histor sinc large-cap peer group
rel biotech peer group histor trade premium multipl
howev note sinc large-cap biotech peer group begun trade
discount broader market
figur illustr recent trade histori share event impact
share either posit neg recal although compani found
complet ipo novemb thu compani overal trade histori
somewhat condens histor inflect point share larg coincid
data result strateg announc competit updat look ahead near
term see multipl data readout continu repres key driver share given
compani stage develop
previous state deriv price target share use sum-of-part dcf
approach primari valuat methodolog believ repres
appropri strategi early-stag develop biotech assumpt
factor analysi includ discount rate given aplss current develop stage
limit public trade histori assign higher discount rate compar
establish commercial-stag compani univers addit incorpor
termin growth rate analys term specif develop program assign
credit effort pnh ga valuat effort assign full credit
probabl success adjust earlier effort indic waiha
left upsid estim await addit data inform
beyond primari valuat analysi share also examin potenti valuat
scenario use altern methodolog note approach also sensit
choic discount rate multipl valuat year figur illustr
potenti fair valu estim use respect approach
select valuat year p/ price-to-earnings analys see prior figur
like repres steady-st period revenu growth compar potenti
launch phase addit adher discount rate also consist
rate use primari valuat methodolog appropri pre-commerci
likewis current mean peer revenu multipl rang consensu revenu
mid-cap large-cap group p/ valuat analysi select revenu
multipl discount current mid-cap peer group given aplss develop
stage profil view like eventu peer group discount
futur peer appear warrant given earli natur develop platform
price-to-earnings valuat analysi earn multipl also discount large-cap peer
current lack consist earn histori overal see three approach yield
similar targets/fair valu estim share
share current trade outperform nasdaq biotechnolog
thu far vs base case scenario price target
impli downsid base share current trade see figur
describ detail see downsid delay lower-than-anticip
price and/or unsuccess trial result upsid target realiz via better apl-
uptak commerci market and/or lower discount rate discount rate move
hold assumpt constant fair valu estim
increas figur summar scenario commentari describ
setup detail
note price
near-term potenti top-lin result phase pegasu studi
pnh januari studi incorpor open-label design primari
endpoint focus hemoglobin hb stabil think like scenario
studi reach endpoint intuit make sens blockad hemolysi
pathway intravascular extravascular would lead reduc red blood cell destruct
thu like share react posit news howev see sever key question
address result first safeti profil look like second hb
improv actual lead chang clinic endpoint transfus depend
base convers kol view current primari endpoint hb stabil
nice versu clinic meaning improv function outcom
transfus avoid final still unclear file requir necessari
treatment-nav indic assum addit princ studi data
suffici howev clinicaltri gov indic us-bas site studi
clarifi registr strategi like requir addit dialog fda unlik
manifest top-lin data
current estim alreadi incorpor conserv success scenario pnh
switch market assum switch market opportun patient either via
restrict due ultomiri entranc simpli smaller non-respond popul
downsid impact target limit declin fair valu
pnh incid low per year potenti upsid opportun like limit
see multi-year delay program see downsid
base case assumpt ga impli fair valu sum-of-part
npv analysi although derbi oak pivot studi like complet enrol
end per manag guidanc top-lin data long-term event
base prior studi conduct space think potenti success
indic low figur summar success rate differ therapeut area
transit variou develop phase likelihood approv rate note
ophthalmology-bas therapi likelihood approv focu
period phase approv rel indic stage develop
likelihood approv rate would lower ophthalmolog vertic compar
overal rate dont specif appli probabl success adjust model
estim like likelihood approv phase ga studi
mean estimates/valu give benefit doubt assign
full credit ga segment estim earliest potenti
commerci launch us base current anticip readout time derbi
oak sum-of-part npv analysi suggest opportun contribut
valuat phase studi fail meet primari endpoint could
envis scenario fair valu estim fall remov
ga opportun trial success addit clinic data requir
delay commerci launch time estim push back launch year
would lower fair valu estim ga opportun
origin found spin-out
latter compani start origin focu center also known
compstatin deriv identifi univers pennsylvania late
acquir potentia asset includ right novemb
compani complet initi public offer becam publicly-trad entiti present
program advanc asset pipelin
individu member manag team prior experi
expertis biotechnology/drug develop space repres first effort
corpor framework addit success advanc market
mark inaugur commerci effort end highlight key member
senior manag team current role
dr francoi one co-found current serv compani ceo
presid also member compani board director dr francoi held
role ceo/presid sinc previous head predecessor compani
potentia sinc dr francoi receiv md univers leuven phd
univers louisvil
dr deschatelet serv chief oper offic sinc co-found
compani dr francoi also previous serv role potentia
pharmaceut predecessor compani dr deschatelet receiv phd
univers montreal
mr sullivan join team compani chief offic prior
join mr sullivan serv aju ib invest also manag
director rb citizen mr sullivan hold bs harvard univers
dr grossi serv chief medic offic sinc previous held
role clinic research director potentia predecessor compani prior join dr
grossi member plastic surgeri research laboratori univers louisvil
dr grossi receiv md univers cordoba phd univers
mr townsend join chief commerci offic novemb prior join
team mr townsend serv role commerci corpor develop
inc hold addit experi novarti mr townsend hold
bsc degre univers london uk
cnv choroid neovascular creation new blood vessel eye
guler gokcay bilgir et al multidisciplinari clinic manag paroxysm
luzzatto young kinoshita et al diagnosi manag paroxysm
diagnosi treatment paroxysm nocturn hemoglobinuria review eur
lemal duma -y etienn et al impact eculizumab treatment paroxysm
ozkocaman ozsan et al pesg pnh diagnosi follow-up treatment
chang bressler munoz west racial differ risk
factor incid progress age-rel macular degener salisburi
approach intravitr inject geograph atrophi secondari age-rel
macular degener current drug potenti molecul mol
wu sun complement age-rel macular degener drug
pegcetacoplan geograph atrophi secondari age-rel macular degener
campagn le bere et al target factor
altern complement pathway reduc geograph atrophi progress secondari
ferrara gray honigberg et al efficaci safeti lampalizumab
geograph atrophi due age-rel macular degener jama ophthalmol
kassa ciulla hussain dugel complement inhibit
therapeut strategi retin disord expert opin biol ther
copeland newton hill et al extravascular hemolysi due
patient pnh treat eculizumab defin clinic syndrom blood
kulasekararaj calado scheinberg et al anti-compl treatment
paroxysm nocturn hemoglobinuria time proxim complement inhibit
posit paper saawp ebmt front immunol
complement blockad patient paroxysm nocturn hemoglobinuria receiv
vs eculizumab adult patient pnh naiv complement inhibitor
vs eculizumab adult patient pnh
elebut nakamura et al complement inhibitor eculizumab paroxysm
price target deriv sum-of-part dcf model examin potenti cash flow deriv discount
back per year
risk attain price rate
clinic data emerg clinic studi significantli impact share either posit neg direct
regulatori apelli may employ acceler strategi gain approv regul may requir addit data could alter
requir approv necessit addit longer studi failur gain product label lack certain featur could
limit apelli abil gain traction market
commerci failur execut commerci inabl meet/exce expect impact share
competit updat competitor may posit neg impact share relev competitor includ compani
alexion roch competitor like emerg time
generic/biosimilar entri new gener biosimilar agent may put pressur apelli exist market product
limit compani abil realiz increas price
singl product risk major apelli develop effort relat drug deem unsaf unabl
advanc share like neg impact
laura chico certifi view express report accur reflect person opinion
directli indirectli receiv compens payment connect specif recommend view contain
report
outperform expect total return stock outperform rel median total return analyst analyst
team coverag univers next month
neutral expect total return stock perform in-lin median total return analyst analyst team
coverag univers next month
under-perform expect total return stock under-perform rel median total return analyst
analyst team coverag univers next month
invest rate base expect perform stock base anticip total return price target rel
stock analyst coverag univers analyst team coverag
novemb
novemb
distribut rate requir finra rule howev ws stock rate outperform neutral under-perform
close conform buy hold sell respect pleas note howev definit ws stock rate
rel basi
analyst respons prepar research report receiv compens base specif invest bank activ
analyst receiv compens base upon variou factor includ ws total revenu portion gener
ws invest bank activ
